<DOC>
	<DOCNO>NCT01881958</DOCNO>
	<brief_summary>Type 1 diabetes cause autoimmune process result selective destruction pancreatic insulin-secreting beta-cell . DiaPep277® small , lyophilized powder contain 24 Amino-acids . We prove former study DiaPep277® slow beta cell destruction pancreas therefore decelerate progress Diabetes . The objective study ass efficacy safety administrate DiaPep277® type 1 diabetes patient .</brief_summary>
	<brief_title>The Safety Efficacy Administrating DiaPep277® Vaccination Type 1 Diabetes Patients .</brief_title>
	<detailed_description />
	<criteria>1 . Fasting Cpeptide level &gt; = 0.2nmol/L . 2 . Diagnosis type 1 diabetes 3 . No pregnancy plan pregnancy female subject 1 . The subject significant disease condition , include psychiatric disorder substance abuse , opinion Investigator , likely affect subject 's response treatment ability complete study . 2 . The subject history kind malignant tumor ( include basal cell skin cancer ) . 3 . The subject clinical evidence diabetesrelated complication opinion Investigator would interfere subject 's participation and/or completion study . 4 . Subject history endogenous allergic reactivity : Severe allergic reaction severe exacerbation allergic asthma within 12 month prior ScreeningExt Visit . Ongoing systemic asthma treatment . Subjects history life threaten severe allergy , reoccurrence rule base Investigator 's judgment . 5 . The subject know allergy lipid emulsion . 6 . The subject know immune deficiency disease , condition associate immune deficiency . 7 . The subject receive immunosuppressive immunomodulating agent cytotoxic therapy medication opinion Investigator might interfere study . 8 . The subject follow clinically significant laboratory abnormality : Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) great three time upper limit normal ( ULN ) ScreeningExt Visit . Total bilirubin great 1.3 time ULN ScreeningExt Visit . Subjects severe renal failure ScreeningExt visit ( defined glomerular filtration rate &lt; 30 mL/min/1.73 m2 Cockroft und Gault calculation • Clinically significant laboratory abnormality , confirm repeat measurement , may interfere assessment safety / efficacy study drug , hyperglycemia glycosuria ScreeningExt Visit . Fasting triglyceride &lt; 1000 mg/dL ( 11.3 mmol/L ) ScreeningExt Visit . Suitable medical therapy treatment hyperlipidemia allow . 9 . The subject know suspected drug abuser . 10 . The subject know test positive HIV antibody . 11 . The subject chronic hematologic disease . 12 . The subject liver disease cirrhosis chronic active hepatitis .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>